Seminars in hematology最新文献

Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. 第12届Waldenström巨球蛋白血症国际研讨会共识小组关于共价BTK抑制剂不耐受或耐药患者管理的报告。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-04-08 DOI: 10.1053/j.seminhematol.2025.04.004

Jorge J Castillo, Francesco Autore, Neil L Berinstein, Andrew R Branagan, Meletios A Dimopoulos, Carlos Fernandez de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C Minnema, Lugui Qiu, John F Seymour, Josephine M I Vos, Christopher J Patterson, Christian Buske, Jeffrey V Matous, Steven P Treon, M Lia Palomba

{"title":"Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors.","authors":"Jorge J Castillo, Francesco Autore, Neil L Berinstein, Andrew R Branagan, Meletios A Dimopoulos, Carlos Fernandez de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C Minnema, Lugui Qiu, John F Seymour, Josephine M I Vos, Christopher J Patterson, Christian Buske, Jeffrey V Matous, Steven P Treon, M Lia Palomba","doi":"10.1053/j.seminhematol.2025.04.004","DOIUrl":"https://doi.org/10.1053/j.seminhematol.2025.04.004","url":null,"abstract":"<p><p>Over the last decade, covalent Bruton tyrosine kinase (BTK) inhibitors have become a standard option for treating patients with symptomatic Waldenström Macroglobulinemia (WM) in the frontline or relapsed settings. However, the definition of intolerance and resistance to covalent BTK inhibitors has not been established. Understanding the best approaches to managing such patients is crucial to avoiding premature abandonment of effective therapy or pursuing futile therapies unlikely to be effective in controlling symptomatic disease progression. With the advent of noncovalent BTK inhibitors and BCL2 antagonists, in addition to clinical trials evaluating phospholipid-drug conjugates, antibody-drug conjugates, and bispecific antibodies, the present Consensus Panel 5 aims to establish working definitions for intolerance and resistance to covalent BTK inhibitors, as well as provide strategies to identify and manage these issues not infrequently encountered in clinical practice.</p>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters 多发性骨髓瘤临床试验资格现代化，通过血液学参数提高公平性和包容性。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2024.10.008

Lauren Merz , Monique Hartley-Brown , Maureen Achebe , Craig Cole , Bindu Kanapuru , Ola Banjo , George Mulligan , Katie Wozniak , Anne Quinn Young , Hearn Jay Cho

{"title":"Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters","authors":"Lauren Merz , Monique Hartley-Brown , Maureen Achebe , Craig Cole , Bindu Kanapuru , Ola Banjo , George Mulligan , Katie Wozniak , Anne Quinn Young , Hearn Jay Cho","doi":"10.1053/j.seminhematol.2024.10.008","DOIUrl":"10.1053/j.seminhematol.2024.10.008","url":null,"abstract":"<div><div>In the United States, Black people experience multiple myeloma (MM) at a frequency that is more than double that of White people and experience much higher rates of mortality. Despite bearing a disproportionate impact of both MM incidence and mortality, Black patients are significantly underrepresented in most MM clinical trials. This is in part because Black patients experience a higher prevalence of hemoglobinopathies and Duffy-null phenotype, which affect hemoglobin and neutrophil levels, respectively, potentially excluding patients from clinical trials. The Multiple Myeloma Research Foundation (MMRF) has convened a series of Health Equity Summits that include a focus on creating inclusive clinical trials for MM. The present paper, an output of the most recent workshop, focuses on the role of laboratory reference ranges as a barrier to clinical trial participation and offers tangible steps to improve the enrollment of a diverse and representative population.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"62 1","pages":"Pages 38-42"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

outside front cover, PMS 8883 metallic AND 4/C 封面外侧，PMS 8883 金属色和 4/C

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/S0037-1963(25)00004-6

引用次数: 0

FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk 家族事务：剖析遗传因素对多发性骨髓瘤风险的影响。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2024.11.006

Saoirse Bodnar , Tehilla Brander , Julie Gold , Ayuko Iverson , Alessandro Lagana , Kenan Onel , Sundar Jagannath , Samir Parekh , Santiago Thibaud

引用次数: 0

At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics 在骨髓瘤治疗的尖端：对发病机制，建模和治疗的见解

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2025.02.002

Samir Parekh MD

引用次数: 0

The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges 1q 异常在多发性骨髓瘤中的作用：基因组学见解、临床意义和治疗挑战。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2024.10.001

Zachary M. Avigan , Constantine S. Mitsiades , Alessandro Laganà

引用次数: 0

Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma 黑色素瘤抗原基因（MAGE）；多发性骨髓瘤的新功能靶点。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2024.10.007

Anna Huo-Chang Mei , Alessandro Laganà , Roman Osman , Hearn Jay Cho

{"title":"Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma","authors":"Anna Huo-Chang Mei , Alessandro Laganà , Roman Osman , Hearn Jay Cho","doi":"10.1053/j.seminhematol.2024.10.007","DOIUrl":"10.1053/j.seminhematol.2024.10.007","url":null,"abstract":"<div><div>Melanoma Antigen Genes (MAGE) are expressed in a broad range of cancers, including multiple myeloma. MAGE have been under investigation for more than 3 decades as targets for immune therapy, while in parallel, interrogation of their functions has revealed activities that may be particularly critical in multiple myeloma. MAGE-C1 is expressed in about 75% of newly diagnosed cases and this is maintained through the natural history of the disease. In contrast, MAGE-A3 is expressed in about 35% of newly diagnosed cases, but this increases to more than 75% after relapse. MAGE-A3 expression was associated with poor clinical outcome and resistance to chemotherapy. Translational studies have revealed that MAGE-A3 regulates cell cycling and apoptosis in myeloma cells. Genomic, gene expression, and multiomic studies demonstrate relations with high-risk subgroups of patients. MAGE-A3 mediates these functions through partnership with Kap1 to form a ubiquitin ligase complex. Structural analysis of the interaction between MAGE-A3 and Kap1 gives insight into the biochemical activity and substrate specificity and suggests novel pharmacologic strategies to inhibit them. These studies demonstrating MAGE-A3 oncogenic functions suggest that it may also be a suitable target for small molecule inhibition in multiple myeloma that may be broadly applicable to other cancers that express it.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"62 1","pages":"Pages 43-49"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoldering multiple myeloma: Integrating biology and risk into management 燃烧性多发性骨髓瘤：将生物学和风险纳入管理。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2024.10.002

Roshani Patel , Elizabeth Hill , Madhav Dhodapkar

引用次数: 0

Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies CAR - t细胞和双特异性抗体治疗时代的髓外骨髓瘤。

IF 5 3区医学

Seminars in hematology Pub Date : 2025-02-01 DOI: 10.1053/j.seminhematol.2025.02.001

Larysa Sanchez, Shambavi Richard

引用次数: 0

Immunocompetent mouse models of multiple myeloma 免疫功能正常的多发性骨髓瘤小鼠模型。